The main objective of iNANOVAC4CANCER is to establish technical and commercial viability for a personalized biohybrid and biodegradable nanovaccine platform, a novel patient-focused nanomaterial-based immunotherapy platform for the treatment of melanoma, prostate, and breast cancers with potential to expand to other cancers and diseases.
Prof. Santos is among the 50 scientists who received an ERC PoC in the second round of 2018. See here for details
The ERC Proof of Concept funding is made available only to those who already have an ERC award to establish proof of concept of an idea that was generated in the course of their ERC-funded projects. For more details about ERC PoC in here
Prof. Santos was an ERC Starting Grant awardee in 2013-2017 with the project "Multistage-Multifunctional Porous Silicon Nanovectors for Directed Theranostics". For more details about the previous ERC StG of Prof. Santos in here
Other news about Prof. Santos' ERC PoC in e-journals (in Portuguese):